Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 589-593

  Yu, Xiaowen ^a,c   Lu, L ^b,c   Cai, Lifeng ^d   Tong, Pei ^a   Tan, Suiyi ^c   Zou, Peng ^c   Meng, Fanxia ^e   Chen, Ying Hua ^a   Jiangb, Shibo ^b,c  

^a Tsinghua University   (China)

^b FUDAN UNIVERSITY   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^e INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C 34; C 52L; CP 32M; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA STRUCTURE; DRUG SENSITIVITY; GENE FUSION; GENE INTERACTION; GENE MUTATION; GIV MOTIF BINDING DOMAIN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID BINDING DOMAIN; N TERMINAL HEPTAD REPEAT; NONHUMAN; POCKET BINDING DOMAIN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; SITE DIRECTED MUTAGENESIS; VIRUS ENTRY; VIRUS GENE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; TERMINAL REPEAT SEQUENCES;

GREAT ISLAND VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862927851     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05066-11     Document Type: Article

References (43)

1. Armand-Ugón M, Gutierrez A, Clotet B, Este JA. 2003. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res. 59:137-142.
2. Cai L, Jiang S. 2010. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem 5:1813-1824.
3. Chan DC, Chutkowski CT, Kim PS. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 95:15613-15617.
4. Chan DC, Fass D, Berger JM, Kim PS. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
5. Chan DC, Kim PS. 1998. HIV entry and its inhibition. Cell 93:681- 684.
6. Chinnadurai R, Rajan D, Munch J, Kirchhoff F. 2007. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J. Virol. 81:6563- 6572.
7. Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M. 2007. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 46: 4360-4369.
8. Dwyer JJ, et al. 2003. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 42:4945-4953.
9. Eckert DM, Kim PS. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777- 810.
10. Eggink D, et al. 2008. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 82:6678-6688.
11. Eron JJ, et al. 2004. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis. 189: 1075-1083.
12. He Y, et al. 2008. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J. Virol. 82:6349-6358.
13. He Y, et al. 2008. Potent HIV fusion inhibitors against enfuvirtideresistant HIV-1 strains. Proc. Natl. Acad. Sci. U. S. A. 105:16332-16337.
14. He Y, et al. 2008. Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J. Virol. 82: 11129-11139.
15. He Y, et al. 2007. Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J. Biol. Chem. 282:25631-25639.
16. He Y, et al. 2008. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283:11126 -11134.
17. Ji H, Shu W, Burling T, Jiang S, Lu M. 1999. Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J. Virol. 73:8578-8586.
18. Jiang S, Lin K, Strick N, Neurath AR. 1993. HIV-1 inhibition by a peptide. Nature 365:113.
19. Jiang S, et al. 2004. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48:4349-4359.
20. Lalezari JP, et al. 2005. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtidecontaining treatment regimen. J. Infect. Dis. 191:1155-1163.
21. Liu K, et al. 2008. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem. 51:7843-7854.
22. Liu S, et al. 2007. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282:9612-9620.
23. Liu S, Lu H, Xu Y, Wu S, Jiang S. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280: 11259-11273.
24. Liu Z, et al. 2011. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 286:3277-3287.
25. Lu M, Blacklow SC, Kim PS. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075-1082.
26. Lu M, Kim PS. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465- 471.
27. McGillick BE, Balius TE, Mukherjee S, Rizzo RC. 2010. Origins of resistance to the HIVgp41 viral entry inhibitor T20. Biochemistry 49: 3575-3592.
28. Menzo S, et al. 2004. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents Chemother. 48:3253-3259.
29. Mink M, et al. 2005. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79: 12447-12454.
30. Moore JP, Doms RW. 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U. S. A. 100:10598 -10602.
31. Pan C, Cai L, Lu H, Qi Z, Jiang S. 2009. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and -resistant HIV type 1 strains. J. Virol. 83:7862-7872.
32. Pan C, Liu S, Jiang S. 2010. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J. Formos. Med. Assoc. 109:94 -105.
33. Pan C, Lu H, Qi Z, Jiang S. 2009. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS 23:639-641.
34. Qi Z, et al. 2008. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J. Biol. Chem. 283:30376 -30384.
35. Ray N, et al. 2007. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 81:3240-3250.
36. Ray N, Blackburn LA, Doms RW. 2009. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 83: 2989-2995.
37. Rimsky LT, Shugars DC, Matthews TJ. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986 -993.
38. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5:725-738.
39. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
40. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-428.
41. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS. 2007. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A. 104: 16828-16833.
42. Weng Y, Weiss CD. 1998. Mutational analysis of residues in the coiledcoil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 72:9676 -9682.
43. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91:9770 -9774.